(9-162) Treatment Tolerance and Disease Relapse/Progression Among CP-CML Patients Treated With Second-Generation TKIs in the First-Line Setting

Wednesday, December 10, 2025

8:30 AM - 9:30 AM

Location: Bayside A, Level 1

Residency Program: Sharp Chula Vista Medical Center
Residency Program Type: PGY1 (Pharmacy)
Residency Program Location: California

Co-Author(s): Michael Stouffer

Primary Author(s)